Experienced in Transient Familial Hyperbilirubinemia

Dr. Rajeev S. Kumar

Neonatology | Pediatrics
1900 W Harrison St, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Transient Familial Hyperbilirubinemia
1900 W Harrison St, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajeev Kumar is a Neonatologist and a Pediatrics provider in Chicago, Illinois. Dr. Kumar is rated as an Experienced provider by MediFind in the treatment of Transient Familial Hyperbilirubinemia. His top areas of expertise are Meconium Aspiration Syndrome, Pneumomediastinum, Gliomatosis Cerebri, Lithotripsy, and Ureteroscopy. Dr. Kumar is currently accepting new patients.

His clinical research consists of co-authoring 234 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Transient Familial Hyperbilirubinemia.

Specialties
Neonatology
Pediatrics
Licenses
Pediatrics in IL
Languages Spoken
English
Hindi
Punjabi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO

Locations

1900 W Harrison St, Chicago, IL 60612
Other Locations
2233 W Division St, Chicago, IL 60622

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: February 28, 2024
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Enrollment Status: Active_not_recruiting
Publish Date: October 23, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Enrollment Status: Terminated
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Diagnostic test
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States
Enrollment Status: Completed
Publish Date: September 21, 2022
Intervention Type: Behavioral
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease
Enrollment Status: Completed
Publish Date: August 08, 2017
Intervention Type: Behavioral
View 15 Less Clinical Trials

234 Total Publications

Harnessing data and control with AI/ML-driven polymerization and copolymerization.
Harnessing data and control with AI/ML-driven polymerization and copolymerization.
Journal: Faraday discussions
Published: October 14, 2025
Similar Doctors
Experienced in Transient Familial Hyperbilirubinemia
Dr. Aisha Jameel
Neonatology | Pediatrics
Experienced in Transient Familial Hyperbilirubinemia
Dr. Aisha Jameel
Neonatology | Pediatrics
180 Harvester Dr Ste 110, 
Burr Ridge, IL 
 (15.9 miles away)
773-834-4064
Languages Spoken:
English
See accepted insurances

Aisha Jameel is a Neonatologist and a Pediatrics provider in Burr Ridge, Illinois. Dr. Jameel is rated as an Experienced provider by MediFind in the treatment of Transient Familial Hyperbilirubinemia. Her top areas of expertise are Hemolytic Disease of the Newborn and Transient Familial Hyperbilirubinemia.

Experienced in Transient Familial Hyperbilirubinemia
Dr. Vishakha C. Nanda
Neonatology | Pediatrics
Experienced in Transient Familial Hyperbilirubinemia
Dr. Vishakha C. Nanda
Neonatology | Pediatrics
2222 W Division St, 
Chicago, IL 
 (2.1 miles away)
312-770-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vishakha Nanda is a Neonatologist and a Pediatrics provider in Chicago, Illinois. Dr. Nanda is rated as an Experienced provider by MediFind in the treatment of Transient Familial Hyperbilirubinemia. Her top areas of expertise are Meconium Aspiration Syndrome, Premature Infant, Jaundice, and Transient Familial Hyperbilirubinemia. Dr. Nanda is currently accepting new patients.

Experienced in Transient Familial Hyperbilirubinemia
Dr. Diana A. Guse
Pediatrics | General Practice | Internal Medicine
Experienced in Transient Familial Hyperbilirubinemia
Dr. Diana A. Guse
Pediatrics | General Practice | Internal Medicine

Endeavor Health Medical Group

1162 W Maple Ave, 
Mundelein, IL 
 (32.9 miles away)
847-367-2400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Diana Guse is a primary care provider, a Pediatrics specialist and a General Practice provider in Mundelein, Illinois. Dr. Guse is rated as an Advanced provider by MediFind in the treatment of Transient Familial Hyperbilirubinemia. Her top areas of expertise are Sinusitis, Empyema, Maturity Onset Diabetes of the Young, and Type 2 Diabetes (T2D). Dr. Guse is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile